| Merck & Co., Inc10 programs in shared conditions | 9 · 6 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Endometrial Neoplasms +6 | sacituzumab tirumotecan, intismeran autogene, calderasib +3 | - Daiichi Sankyo’s datopotamab deruxtecan added to pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT05555732)
- Daiichi Sankyo’s Anti-TA-MUC1/DXd Antibody-drug Conjugate DS-3939a added to pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT07739966)
- Daiichi Sankyo’s Anti-SIRPa Monoclonal Antibody DS-1103 in a combination vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT07739966)
- and 5 more
|
| Fosun Pharma10 programs in shared conditions | 3 · 2 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Leukemia, Myeloid, Acute | dulpatatug, HLX87, hx22 +4 | - Fosun Pharma’s HLX87 in a combination vs trastuzumab deruxtecan (US & EU rights: Daiichi Sankyo) (Breast Neoplasms, NCT07294508)
- Fosun Pharma’s dulpatatug in a combination vs trastuzumab deruxtecan (US & EU rights: Daiichi Sankyo) (Breast Neoplasms, NCT07294508)
|
| Astellas Pharma Inc10 programs in shared conditions | 4 · 3 with both in phase 3Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Urinary Bladder Neoplasms +1 | setidegrasib, enzalutamide, zolbetuximab +1 | - Daiichi Sankyo’s datopotamab deruxtecan added to enfortumab vedotin (US & EU rights: Astellas Pharma Inc) (Carcinoma, Non-Small-Cell Lung, NCT07890714)
- Daiichi Sankyo’s olomorasib in a combination vs enfortumab vedotin (US & EU rights: Astellas Pharma Inc) (Carcinoma, Non-Small-Cell Lung, NCT07890714)
|
| Hoffmann-La Roche10 programs in shared conditions | 4 · 2 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Coronary Artery Disease +1 | inavolisib, giredestrant, bizrolertinib +1 | - Daiichi Sankyo’s trastuzumab deruxtecan vs Ado-Trastuzumab Emtansine (US & EU rights: Hoffmann-La Roche) (Breast Neoplasms, NCT04622319)
- Hoffmann-La Roche’s inavolisib added to trastuzumab deruxtecan (US & EU rights: Daiichi Sankyo) (Breast Neoplasms, NCT03424005)
|
| Jiangsu HengRui Medicine Co., Ltd.26 programs in shared conditions | 7 · 6 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Hypercholesterolemia +4 | HRS-6209, HRS-8080, trastuzumab rezetecan +8 | - Jiangsu HengRui Medicine Co., Ltd.’s trastuzumab rezetecan vs trastuzumab deruxtecan (US & EU rights: Daiichi Sankyo) (Breast Neoplasms, NCT07497386)
|